Literature DB >> 35226188

Uterine fibroid polygenic risk score (PRS) associates and predicts risk for uterine fibroid.

Jacqueline A Piekos1, Jacklyn N Hellwege1,2, Yanfei Zhang3, Eric S Torstenson1,4, Gail P Jarvik5, Ozan Dikilitas6, Iftikhar J Kullo6, Daniel J Schaid7, David R Crosslin5, Sarah A Pendergrass8, Ming Ta Michael Lee3, Dan Roden1,9, Josh C Denny1,10, Todd L Edwards1,4, Digna R Velez Edwards11,12,13.   

Abstract

Uterine fibroids (UF) are common pelvic tumors in women, heritable, and genome-wide association studies (GWAS) have identified ~ 30 loci associated with increased risk in UF. Using summary statistics from a previously published UF GWAS performed in a non-Hispanic European Ancestry (NHW) female subset from the Electronic Medical Records and Genomics (eMERGE) Network, we constructed a polygenic risk score (PRS) for UF. UF-PRS was developed using PRSice and optimized in the separate clinical population of BioVU. PRS was validated using parallel methods of 10-fold cross-validation logistic regression and phenome-wide association study (PheWAS) in a seperate subset of eMERGE NHW females (validation set), excluding samples used in GWAS. PRSice determined pt < 0.001 and after linkage disequilibrium pruning (r2 < 0.2), 4458 variants were in the PRS which was significant (pseudo-R2 = 0.0018, p = 0.041). 10-fold cross-validation logistic regression modeling of validation set revealed the model had an area under the curve (AUC) value of 0.60 (95% confidence interval [CI] 0.58-0.62) when plotted in a receiver operator curve (ROC). PheWAS identified six phecodes associated with the PRS with the most significant phenotypes being 218 'benign neoplasm of uterus' and 218.1 'uterine leiomyoma' (p = 1.94 × 10-23, OR 1.31 [95% CI 1.26-1.37] and p = 3.50 × 10-23, OR 1.32 [95% CI 1.26-1.37]). We have developed and validated the first PRS for UF. We find our PRS has predictive ability for UF and captures genetic architecture of increased risk for UF that can be used in further studies.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Mesh:

Year:  2022        PMID: 35226188      PMCID: PMC9420161          DOI: 10.1007/s00439-022-02442-z

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   5.881


  4 in total

1.  Reproductive characteristics and risk of uterine leiomyomata.

Authors:  Kathryn L Terry; Immaculata De Vivo; Susan E Hankinson; Stacey A Missmer
Journal:  Fertil Steril       Date:  2010-06-08       Impact factor: 7.329

2.  Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study.

Authors:  G D Coronado; L M Marshall; S M Schwartz
Journal:  Obstet Gynecol       Date:  2000-05       Impact factor: 7.661

Review 3.  Developing and evaluating polygenic risk prediction models for stratified disease prevention.

Authors:  Nilanjan Chatterjee; Jianxin Shi; Montserrat García-Closas
Journal:  Nat Rev Genet       Date:  2016-05-03       Impact factor: 53.242

4.  The eMERGE genotype set of 83,717 subjects imputed to ~40 million variants genome wide and association with the herpes zoster medical record phenotype.

Authors:  Ian B Stanaway; Taryn O Hall; Elisabeth A Rosenthal; Melody Palmer; Vivek Naranbhai; Rachel Knevel; Bahram Namjou-Khales; Robert J Carroll; Krzysztof Kiryluk; Adam S Gordon; Jodell Linder; Kayla Marie Howell; Brandy M Mapes; Frederick T J Lin; Yoonjung Yoonie Joo; M Geoffrey Hayes; Ali G Gharavi; Sarah A Pendergrass; Marylyn D Ritchie; Mariza de Andrade; Damien C Croteau-Chonka; Soumya Raychaudhuri; Scott T Weiss; Matt Lebo; Sami S Amr; David Carrell; Eric B Larson; Christopher G Chute; Laura Jarmila Rasmussen-Torvik; Megan J Roy-Puckelwartz; Patrick Sleiman; Hakon Hakonarson; Rongling Li; Elizabeth W Karlson; Josh F Peterson; Iftikhar J Kullo; Rex Chisholm; Joshua Charles Denny; Gail P Jarvik; David R Crosslin
Journal:  Genet Epidemiol       Date:  2018-10-08       Impact factor: 2.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.